<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001867899</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001730430</issuerCik>
      <issuerName>Kiniksa Pharmaceuticals International, plc</issuerName>
      <secFileNumber>001-38492</secFileNumber>
      <issuerAddress>
        <com:street1>23 OLD BOND STREET, FLOOR 3</com:street1>
        <com:city>LONDON</com:city>
        <com:stateOrCountry>X0</com:stateOrCountry>
        <com:zipCode>WIS 4PZ</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>7814319100</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Tessari Eben</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Charles Schwab &amp; Co., Inc.</name>
        <address>
          <com:street1>3000 Schwab Way</com:street1>
          <com:city>Westlake</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>76262</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>18900</noOfUnitsSold>
      <aggregateMarketValue>542860.00</aggregateMarketValue>
      <noOfUnitsOutstanding>42336227</noOfUnitsOutstanding>
      <approxSaleDate>07/14/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>07/14/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Employee Stock Option Exercise</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>6500</amountOfSecuritiesAcquired>
      <paymentDate>07/14/2025</paymentDate>
      <natureOfPayment>Broker Payment for Cashless Exercise</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>09/16/2015</acquiredDate>
      <natureOfAcquisitionTransaction>Founders Shares</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>7000</amountOfSecuritiesAcquired>
      <paymentDate>09/16/2015</paymentDate>
      <natureOfPayment>NA</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>09/02/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>151</amountOfSecuritiesAcquired>
      <paymentDate>09/02/2023</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>09/01/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1926</amountOfSecuritiesAcquired>
      <paymentDate>09/01/2023</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>03/20/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Performance Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>549</amountOfSecuritiesAcquired>
      <paymentDate>03/20/2023</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>03/16/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1387</amountOfSecuritiesAcquired>
      <paymentDate>03/16/2023</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Ordinary Shares</securitiesClassTitle>
      <acquiredDate>09/02/2022</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Lapse</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Kiniksa Pharmaceuticals, Ltd</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1387</amountOfSecuritiesAcquired>
      <paymentDate>09/02/2022</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>04/14/2025</saleDate>
      <amountOfSecuritiesSold>12000</amountOfSecuritiesSold>
      <grossProceeds>245852.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>05/19/2025</saleDate>
      <amountOfSecuritiesSold>12000</amountOfSecuritiesSold>
      <grossProceeds>316898.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>06/09/2025</saleDate>
      <amountOfSecuritiesSold>10319</amountOfSecuritiesSold>
      <grossProceeds>313453.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>06/10/2025</saleDate>
      <amountOfSecuritiesSold>15506</amountOfSecuritiesSold>
      <grossProceeds>472239.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>06/11/2025</saleDate>
      <amountOfSecuritiesSold>45042</amountOfSecuritiesSold>
      <grossProceeds>1374277.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Eben Tessari</name>
        <address>
          <com:street1>100 Hayden Avenue</com:street1>
          <com:city>Lexington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02421</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Kiniksa Pharmaceuticals International, plc</securitiesClassTitle>
      <saleDate>06/16/2025</saleDate>
      <amountOfSecuritiesSold>17300</amountOfSecuritiesSold>
      <grossProceeds>489171.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>07/14/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>04/29/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>Eben Tessari</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 10109}]
144
0001867899
XXXXXXXX
LIVE
0001730430
Kiniksa Pharmaceuticals International, plc
001-38492
23 OLD BOND STREET, FLOOR 3
LONDON
X0
WIS 4PZ
7814319100
Tessari Eben
Officer
Class A Ordinary Shares
Charles Schwab & Co., Inc.
3000 Schwab Way
Westlake
TX
76262
18900
542860.00
42336227
07/14/2025
NASDAQ
Class A Ordinary Shares
07/14/2025
Employee Stock Option Exercise
Kiniksa Pharmaceuticals, Ltd
N
6500
07/14/2025
Broker Payment for Cashless Exercise
Class A Ordinary Shares
09/16/2015
Founders Shares
Kiniksa Pharmaceuticals, Ltd
N
7000
09/16/2015
NA
Class A Ordinary Shares
09/02/2023
Restricted Stock Lapse
Kiniksa Pharmaceuticals, Ltd
N
151
09/02/2023
Equity Compensation
Class A Ordinary Shares
09/01/2023
Restricted Stock Lapse
Kiniksa Pharmaceuticals, Ltd
N
1926
09/01/2023
Equity Compensation
Class A Ordinary Shares
03/20/2023
Performance Stock Lapse
Kiniksa Pharmaceuticals, Ltd
N
549
03/20/2023
Equity Compensation
Class A Ordinary Shares
03/16/2023
Restricted Stock Lapse
Kiniksa Pharmaceuticals, Ltd
N
1387
03/16/2023
Equity Compensation
Class A Ordinary Shares
09/02/2022
Restricted Stock Lapse
Kiniksa Pharmaceuticals, Ltd
N
1387
09/02/2022
Equity Compensation
N
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
04/14/2025
12000
245852.00
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
05/19/2025
12000
316898.00
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
06/09/2025
10319
313453.00
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
06/10/2025
15506
472239.00
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
06/11/2025
45042
1374277.00
Eben Tessari
100 Hayden Avenue
Lexington
MA
02421
Kiniksa Pharmaceuticals International, plc
06/16/2025
17300
489171.00
07/14/2025
04/29/2024
Eben Tessari